When exenatide received FDA approval in 2005, GLP-1R was understood primarily as a pancreatic target, and the incretin system looked like a clean metabolic story
1 Later, the American Association for the Study of Liver Diseases led the adoption of a new multisociety Delphi consensus in 2023, proposing metabolic dysfunction-associated steatotic liver disease (MASLD) as another replacement term for nonalcoholic fatty liver disease
Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, and Drucker DJ
Convenience: Moreover, while IV and IM injections call for a healthcare professional to assist, subcutaneous injections are uncomplicated
Most workouts cant protect your muscle on GLP-1s this one does